EVOLENT HEALTH INC - A (EVH) Stock Fundamental Analysis
USA - NYSE:EVH - US30050B1017 - Common Stock
4.14 USD
+0.45 (+12.2%)
4.17 USD
+0.03 (+0.72%)
EVH gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 35 industry peers in the Health Care Technology industry. EVH may be in some trouble as it scores bad on both profitability and health. EVH is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
EVH had negative earnings in the past year.
In the past year EVH has reported a negative cash flow from operations.
EVH had negative earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: EVH reported negative operating cash flow in multiple years.
1.2 Ratios
With a decent Return On Assets value of -7.37%, EVH is doing good in the industry, outperforming 65.71% of the companies in the same industry.
EVH has a Return On Equity of -21.48%. This is comparable to the rest of the industry: EVH outperforms 60.00% of its industry peers.
EVH has a Return On Invested Capital of 0.68%. This is in the better half of the industry: EVH outperforms 65.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.37% | ||
| ROE | -21.48% | ||
| ROIC | 0.68% |
ROA(3y)-3.35%
ROA(5y)-7.41%
ROE(3y)-7.16%
ROE(5y)-16.17%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
EVH has a better Operating Margin (0.86%) than 65.71% of its industry peers.
With a Gross Margin value of 18.42%, EVH is not doing good in the industry: 82.86% of the companies in the same industry are doing better.
EVH's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 0.86% | ||
| PM (TTM) | N/A | ||
| GM | 18.42% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-19.51%
GM growth 5Y-10.71%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), EVH is destroying value.
EVH has more shares outstanding than it did 1 year ago.
The number of shares outstanding for EVH has been increased compared to 5 years ago.
EVH has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 0.59, we must say that EVH is in the distress zone and has some risk of bankruptcy.
EVH's Altman-Z score of 0.59 is in line compared to the rest of the industry. EVH outperforms 57.14% of its industry peers.
EVH has a Debt/Equity ratio of 1.26. This is a high value indicating a heavy dependency on external financing.
EVH has a Debt to Equity ratio of 1.26. This is amonst the worse of the industry: EVH underperforms 80.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.26 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.59 |
ROIC/WACC0.08
WACC8.27%
2.3 Liquidity
EVH has a Current Ratio of 1.33. This is a normal value and indicates that EVH is financially healthy and should not expect problems in meeting its short term obligations.
EVH has a Current ratio of 1.33. This is in the lower half of the industry: EVH underperforms 71.43% of its industry peers.
A Quick Ratio of 1.33 indicates that EVH should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.33, EVH is doing worse than 71.43% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.33 | ||
| Quick Ratio | 1.33 |
3. Growth
3.1 Past
The earnings per share for EVH have decreased strongly by -101.10% in the last year.
Measured over the past years, EVH shows a very strong growth in Earnings Per Share. The EPS has been growing by 220.75% on average per year.
EVH shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -16.65%.
The Revenue has been growing by 30.04% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-101.1%
EPS 3Y220.75%
EPS 5YN/A
EPS Q2Q%25%
Revenue 1Y (TTM)-16.65%
Revenue growth 3Y41.17%
Revenue growth 5Y30.04%
Sales Q2Q%-22.83%
3.2 Future
The Earnings Per Share is expected to grow by 15.96% on average over the next years. This is quite good.
EVH is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.79% yearly.
EPS Next Y-62.35%
EPS Next 2Y-3.73%
EPS Next 3Y6.39%
EPS Next 5Y15.96%
Revenue Next Year-26.38%
Revenue Next 2Y-2.96%
Revenue Next 3Y2.81%
Revenue Next 5Y6.79%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
EVH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 6.77, the valuation of EVH can be described as very cheap.
EVH's Price/Forward Earnings ratio is rather cheap when compared to the industry. EVH is cheaper than 94.29% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of EVH to the average of the S&P500 Index (34.46), we can say EVH is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 6.77 |
4.2 Price Multiples
80.00% of the companies in the same industry are more expensive than EVH, based on the Enterprise Value to EBITDA ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 11.66 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.73%
EPS Next 3Y6.39%
5. Dividend
5.1 Amount
EVH does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
4.14
+0.45 (+12.2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners108.7%
Inst Owner Change5.61%
Ins Owners1.53%
Ins Owner Change9.91%
Market Cap486.49M
Revenue(TTM)2.05B
Net Income(TTM)-180.88M
Analysts83.33
Price Target15.98 (285.99%)
Short Float %14.75%
Short Ratio4.8
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-139.54%
Min EPS beat(2)-226.45%
Max EPS beat(2)-52.63%
EPS beat(4)0
Avg EPS beat(4)-162.45%
Min EPS beat(4)-332.96%
Max EPS beat(4)-37.77%
EPS beat(8)3
Avg EPS beat(8)-78.52%
EPS beat(12)6
Avg EPS beat(12)-25.77%
EPS beat(16)10
Avg EPS beat(16)442.42%
Revenue beat(2)1
Avg Revenue beat(2)-1.34%
Min Revenue beat(2)-4.24%
Max Revenue beat(2)1.56%
Revenue beat(4)2
Avg Revenue beat(4)-0.09%
Min Revenue beat(4)-4.24%
Max Revenue beat(4)4.03%
Revenue beat(8)5
Avg Revenue beat(8)0.67%
Revenue beat(12)7
Avg Revenue beat(12)0.38%
Revenue beat(16)10
Avg Revenue beat(16)1.03%
PT rev (1m)0%
PT rev (3m)-12.67%
EPS NQ rev (1m)-7.86%
EPS NQ rev (3m)22.25%
EPS NY rev (1m)0.82%
EPS NY rev (3m)-30.29%
Revenue NQ rev (1m)-1.8%
Revenue NQ rev (3m)-7.04%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-8.38%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 6.77 | ||
| P/S | 0.24 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.58 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.66 |
EPS(TTM)-0.01
EYN/A
EPS(NY)0.61
Fwd EY14.78%
FCF(TTM)-0.58
FCFYN/A
OCF(TTM)-0.31
OCFYN/A
SpS17.48
BVpS7.17
TBVpS-7.29
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.37% | ||
| ROE | -21.48% | ||
| ROCE | 0.87% | ||
| ROIC | 0.68% | ||
| ROICexc | 0.73% | ||
| ROICexgc | 6.52% | ||
| OM | 0.86% | ||
| PM (TTM) | N/A | ||
| GM | 18.42% | ||
| FCFM | N/A |
ROA(3y)-3.35%
ROA(5y)-7.41%
ROE(3y)-7.16%
ROE(5y)-16.17%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-19.51%
GM growth 5Y-10.71%
F-Score4
Asset Turnover0.84
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.26 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 9.01 | ||
| Cap/Depr | 32.44% | ||
| Cap/Sales | 1.58% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.33 | ||
| Quick Ratio | 1.33 | ||
| Altman-Z | 0.59 |
F-Score4
WACC8.27%
ROIC/WACC0.08
Cap/Depr(3y)38.35%
Cap/Depr(5y)41.66%
Cap/Sales(3y)1.98%
Cap/Sales(5y)2.43%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-101.1%
EPS 3Y220.75%
EPS 5YN/A
EPS Q2Q%25%
EPS Next Y-62.35%
EPS Next 2Y-3.73%
EPS Next 3Y6.39%
EPS Next 5Y15.96%
Revenue 1Y (TTM)-16.65%
Revenue growth 3Y41.17%
Revenue growth 5Y30.04%
Sales Q2Q%-22.83%
Revenue Next Year-26.38%
Revenue Next 2Y-2.96%
Revenue Next 3Y2.81%
Revenue Next 5Y6.79%
EBIT growth 1Y218.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year303.86%
EBIT Next 3Y83.64%
EBIT Next 5Y53.42%
FCF growth 1Y-223.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-140.71%
OCF growth 3Y-21.47%
OCF growth 5YN/A
EVOLENT HEALTH INC - A / EVH FAQ
What is the fundamental rating for EVH stock?
ChartMill assigns a fundamental rating of 2 / 10 to EVH.
What is the valuation status for EVH stock?
ChartMill assigns a valuation rating of 3 / 10 to EVOLENT HEALTH INC - A (EVH). This can be considered as Overvalued.
Can you provide the profitability details for EVOLENT HEALTH INC - A?
EVOLENT HEALTH INC - A (EVH) has a profitability rating of 2 / 10.
What is the financial health of EVOLENT HEALTH INC - A (EVH) stock?
The financial health rating of EVOLENT HEALTH INC - A (EVH) is 1 / 10.